As global biotech investment has cooled since the biotech bull market of 2021, some companies have looked to cut more than 25% of their staff.
Read the full post on Becker's Hospital Review - Healthcare News
As global biotech investment has cooled since the biotech bull market of 2021, some companies have looked to cut more than 25% of their staff.
Read the full post on Becker's Hospital Review - Healthcare News